{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"9.280","floor":"8.280"},"ipodate":{"start":"2018-08-31 00:00:00","end":"2018-09-05 00:00:00"},"minimumcapital":"4686.76","subscribed":"0.50","marketcap":"87.10億","H_marketcap":"--","pe":"--","codesrate":"100.00","link":"https://staticpdf.iqdii.com/stockdata/notice/Prospectus/02552/LTN20180831038_C.pdf","ipopricing":"8.280","resultdate":"2018-09-13 00:00:00","enddate":"2018-09-05 00:00:00","listeddate":"2018-09-14 00:00:00","issuenumber":"10475.60萬","issuenumberhK":"521.75萬","issuenumberother":"9953.85萬","grayprice":"8.20","sponsors":"高盛(亞洲)有限責任公司,中信里昂證券資本市場有限公司","raisemoney":"78060.00萬","use":"1、約39%（或304.4百萬港元）將用于在未來兩年內完成Dorzagliatin進行III期試驗， 其中約35%分配至單藥治療試驗，而65%則分配至與二甲雙胍聯合療法試驗；\n2、約9%（或70.3百萬港元）將用于在未來三年內涉及Dorzagliatin的進一步研發，將包括聯用試驗；\n3、約27%（或210.8百萬港元）將用于在未來三年內在中國推出Dorzagliatin及商業 化，包括營銷、銷售及生產；\n4、約11%（或85.9百萬港元）將用于在未來三年內進一步研究涉及Dorzagliatin的固 定劑量組合及個人化糖尿病以及mGLUR5的研究；\n5、約4%（或31.2百萬港元）將用于在未來三年內開拓直接與糖尿病或我們認為重大醫 療需求而未被滿足的新治療領域有關的其他特許及合伙商機；\n6、約10%（或78.1百萬港元）將用作我們的一般公司及營運資金用途。","shares":500,"leadagent":"高盛(亞洲)有限責任公司,中信里昂證券有限公司,瑞士銀行香港分行,國泰君安證券(香港)有限公司","bookrunners":"高盛(亞洲)有限責任公司,中信里昂證券有限公司,瑞士銀行香港分行","coordinator":"高盛(亞洲)有限責任公司,中信里昂證券有限公司,瑞士銀行香港分行","firstDayOpen":"8.28","IsEiio":0,"Interestdays":8,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"高盛(亞洲)有限責任公司","code":"E02552","name":"華領醫藥－Ｂ","fullname":"華領醫藥"},"institutioninfo":{"principaloffice":"中國上海市愛迪生路275號華領醫藥","registrars":"卓佳證券登記有限公司","registrarstel":"(852)2980 1333 ","chairman":"Robert Taylor NELSEN","secretary":"袁頴欣","telephone":"(8621) 5886 9997","substantialshareholders":"ARCH(11.89%),Venrock實體(9.84%),Wuxi(7.04%),Harvest Cayman(6.24%),Eight Roads實體(5.32%)","principalactivities":"華領醫藥是一家中國藥物開發公司，目前致力于開發用于治療2型糖尿病的全球首創口服新藥Dorzagliatin或HMS5552。","website":"http://www.huamedicine.com"},"managerinfo":[{"managername":"陳力","post":"創辦人、行政總裁、首席科學官兼執行董事","rankno":1},{"managername":"林潔誠","post":"執行副總裁、首席財務官兼執行董事","rankno":2},{"managername":"Robert Taylor NELSEN","post":"主席兼非執行董事","rankno":3}],"investorinfo":[],"TotalShareholdingPercentage":0},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":543}